| The Eye Care Group | |
| 250 Indian River Rd, Orange, Connecticut 06477 | |
| (203) 597-9100 |
| Name | The Eye Care Group |
|---|---|
| Organization Name | The Eye Care Group |
| Location | 250 Indian River Rd, Orange, Connecticut 06477 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Phone | (203) 597-9100 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Gastrointestinal specialists from the American College of Gastroenterology applaud President Obama's call to cover preventive screening tests, such as breast cancer exams and colonoscopy. In his health care speech to a joint session of Congress last night, the President argued that "there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse. That makes sense."
COPAN announced this week that it has received the Japanese patent for the invention of flocked swabs, FLOQSwabs, for collection and transfer of biological samples. The Japanese flocked swabs patent (2007-523663) is the latest addition to a growing number of patents held by COPAN across the world for the use of flocked swabs for collection and transfer of biological samples, including the Australian patent (2004226798) granted earlier this year, a European patent that covers several countries (1608268), a Canadian patent (2515205), and New Zealand patent (541560).
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
› Verified 3 days ago
| NPI Number | 1790114866 |
| Organization Name | THE EYE CARE GROUP |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 250 Indian River Road, Orange, CT 06477 |
| Phone Number | 203-597-9100 |
News Archive
Gastrointestinal specialists from the American College of Gastroenterology applaud President Obama's call to cover preventive screening tests, such as breast cancer exams and colonoscopy. In his health care speech to a joint session of Congress last night, the President argued that "there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse. That makes sense."
COPAN announced this week that it has received the Japanese patent for the invention of flocked swabs, FLOQSwabs, for collection and transfer of biological samples. The Japanese flocked swabs patent (2007-523663) is the latest addition to a growing number of patents held by COPAN across the world for the use of flocked swabs for collection and transfer of biological samples, including the Australian patent (2004226798) granted earlier this year, a European patent that covers several countries (1608268), a Canadian patent (2515205), and New Zealand patent (541560).
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
› Verified 3 days ago
News Archive
Gastrointestinal specialists from the American College of Gastroenterology applaud President Obama's call to cover preventive screening tests, such as breast cancer exams and colonoscopy. In his health care speech to a joint session of Congress last night, the President argued that "there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse. That makes sense."
COPAN announced this week that it has received the Japanese patent for the invention of flocked swabs, FLOQSwabs, for collection and transfer of biological samples. The Japanese flocked swabs patent (2007-523663) is the latest addition to a growing number of patents held by COPAN across the world for the use of flocked swabs for collection and transfer of biological samples, including the Australian patent (2004226798) granted earlier this year, a European patent that covers several countries (1608268), a Canadian patent (2515205), and New Zealand patent (541560).
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).
St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.
› Verified 3 days ago
Cvs Pharmacy #02097 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 279 Boston Post Rd, Orange, Connecticut 06477 Phone: (203) 795-4704 | |
Cvs Pharmacy #17071 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 25 Boston Post Rd, Orange, Connecticut 06477 Phone: (203) 859-3695 | |
Connecticut Orthopaedic Specialists Type: Medicare Supplier Location: 330 Boston Post Rd, Orange, Connecticut 06477 Phone: (203) 795-4784 | |
Connecticut Orthopaedic Specialists Type: Medicare Supplier Location: 464 Boston Post Rd, Orange, Connecticut 06477 Phone: (203) 752-3100 | |
Med-aid Llc Type: Medicare Supplier Location: 284 Racebrook Rd, Orange, Connecticut 06477 Phone: (203) 891-8945 |